Erlotinib and the risk of oral cancer the erlotinib Prevention of Oral Cancer (EPOC) randomized clinical trial Academic Article uri icon

Overview

MeSH Major

  • Anticarcinogenic Agents
  • Erlotinib Hydrochloride
  • Mouth Neoplasms
  • Precancerous Conditions
  • Protein Kinase Inhibitors

abstract

  • clinicaltrials.gov Identifier: NCT00402779.

publication date

  • January 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4771491

Digital Object Identifier (DOI)

  • 10.1001/jamaoncol.2015.4364

PubMed ID

  • 26540028

Additional Document Info

start page

  • 209

end page

  • 16

volume

  • 2

number

  • 2